Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

654
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
654
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

429
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
429
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

404
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
404
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

627
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
627
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.3K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.3K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

473
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
473

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed emergence of parkinson's disease after reversible manganese-induced parkinsonism: a case report.

BMC neurology·2025
Same author

Therapeutic Potential of Porcine Brain-Derived Peptide Mixture (PBDP) in Alzheimer's Disease: An Exploratory Study on Quantitative Electroencephalography (qEEG) Changes.

Neuropsychiatric disease and treatment·2025
Same author

Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study.

Journal of neural transmission (Vienna, Austria : 1996)·2024
Same author

Differential induction of Parieto-motor plasticity in writer's cramp and cervical dystonia.

Neurobiology of disease·2024
Same author

Association between striatal amyloid deposition and motor prognosis in Parkinson's disease.

European journal of neurology·2024
Same author

Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.

Movement disorders clinical practice·2024
Same journal

TBC1D2B-related Neurodevelopmental Disorder with Gingival Overgrowth and Movement Disorders: A Case Series and Literature Review.

Journal of movement disorders·2026
Same journal

Distinct and Combined Cognitive Profiles associated with Depression and Anxiety in Early Parkinson's Disease.

Journal of movement disorders·2026
Same journal

Improvement of Refractory Restless Legs Syndrome in a Parkinson's Disease Patient After Semaglutide Treatment: A Novel Clinical Observation.

Journal of movement disorders·2026
Same journal

Serum Neuronal Extracellular vesicles for RT-QuIC assay to detect Pathological α-Synuclein in Synucleinopathies.

Journal of movement disorders·2026
Same journal

Psychosis after weight loss during continuous subcutaneous foslevodopa/foscarbidopa therapy - a case series.

Journal of movement disorders·2026
Same journal

Attentional or Non-Tactile Sensory Tricks in Idiopathic Cervical Dystonia: A Phenomenological Observation.

Journal of movement disorders·2026
See all related articles

Related Experiment Video

Updated: Sep 24, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K

Mosapride-Induced Movement Disorders

Sang-Wook Hong1, Hae-Won Shin1

  • 1Department of Neurology, Chung-Ang University Hospital, Seoul, Korea.

Journal of Movement Disorders
|May 9, 2022
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Swimming Induced Paralysis to Assess Dopamine Signaling in Caenorhabditis elegans
07:36

Swimming Induced Paralysis to Assess Dopamine Signaling in Caenorhabditis elegans

Published on: April 3, 2019

7.9K
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

11.6K

Related Experiment Videos

Last Updated: Sep 24, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K
Swimming Induced Paralysis to Assess Dopamine Signaling in Caenorhabditis elegans
07:36

Swimming Induced Paralysis to Assess Dopamine Signaling in Caenorhabditis elegans

Published on: April 3, 2019

7.9K
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

11.6K